ライフサイエンスコーパス: cryptococcal meningitis

1 be considered for point-of-care diagnosis of cryptococcal meningitis.

2 sease severity and outcome in HIV-associated cryptococcal meningitis.

3 rebrospinal fluid samples from patients with cryptococcal meningitis.

4 tosine as first-line induction treatment for cryptococcal meningitis.

5 to safe and effective antifungal therapy for cryptococcal meningitis.

6 d with improved survival among patients with cryptococcal meningitis.

7 lus 5-FC for the treatment of HIV-associated cryptococcal meningitis.

8 One patient developed Cryptococcal meningitis.

9 s to promote increased ICP in a rat model of cryptococcal meningitis.

10 acquired immunodeficiency syndrome and acute cryptococcal meningitis.

11 ain was also avirulent in an animal model of cryptococcal meningitis.

12 gnificantly attenuated in an animal model of cryptococcal meningitis.

13 e no longer pathogenic in an animal model of cryptococcal meningitis.

14 marker of disease severity and mortality in cryptococcal meningitis.

15 fungus in infected mice and in patients with cryptococcal meningitis.

16 ws that (1,3)-beta-d-glucan is detectable in cryptococcal meningitis.

17 pathogen responsible for cryptococcosis and cryptococcal meningitis.

18 cytosine for the treatment of HIV-associated cryptococcal meningitis.

19 had begun following antifungal treatment of cryptococcal meningitis.

20 or older and presenting with a first case of cryptococcal meningitis.

21 marker of disease severity and mortality in cryptococcal meningitis.

22 g of innate and adaptive immune responses in cryptococcal meningitis.

23 l recipient survived following treatment for cryptococcal meningitis.

24 e preferred options for induction therapy of cryptococcal meningitis.

25 e mortality among adults with HIV-associated cryptococcal meningitis.

26 phan was also associated with mortality from cryptococcal meningitis.

27 HIV-infected Ugandan adults at diagnosis of cryptococcal meningitis.

28 e impact of ART interruption at diagnosis of cryptococcal meningitis.

29 ymptoms only, along with controls of primary cryptococcal meningitis.

30 human immunodeficiency virus at diagnosis of cryptococcal meningitis.

31 FA is associated with all-cause mortality in cryptococcal meningitis.

32 s, 50 with bacterial meningitis, and 60 with cryptococcal meningitis.

33 tococcal antigen (CrAg) precedes symptomatic cryptococcal meningitis.

34 on serum and among hospitalized adults with cryptococcal meningitis.

35 e positive among 30 hospitalized adults with cryptococcal meningitis.

36 e used to treat patients with HIV-associated cryptococcal meningitis.

37 e in human immunodeficiency virus-associated cryptococcal meningitis.

38 red to participants with confirmed CSF CrAg+ cryptococcal meningitis.

39 an opportunistic pathogen that causes fatal cryptococcal meningitis.

40 of people who are developing and dying from cryptococcal meningitis.

41 , but their use is untested in patients with cryptococcal meningitis.

42 mulating factor (GM-CSF) autoantibodies with cryptococcal meningitis.

43 important contributor to virulence in human cryptococcal meningitis.

44 Cryptococcal meningitis (148 [55%] of 269) was the leadi

45 One survivor had suffered cryptococcal meningitis 2 years prior.

46 mptomatic cryptococcal antigenemia (32%) and cryptococcal meningitis (31%; P = .91).

47 mptom onset) was 47% among first episodes of cryptococcal meningitis, 31% in culture-positive relapse

48 3%] of 90) was the leading cause followed by cryptococcal meningitis (36 [40%] of 90).

49 Among 489 participants with cryptococcal meningitis, 40% (194/489) received blood Cr

50 reened for HIV-associated meningitis, 60 had cryptococcal meningitis (59 CrAg positive [CrAg(+)] by L

51 ormans var. grubii is the causative agent of cryptococcal meningitis, a significant source of mortali

52 Cryptococcal meningitis accounts for 1 in 5 AIDS-related

53 Cryptococcal meningitis accounts for 20 to 25% of acquir

54 nal fluid (CSF) samples for the diagnosis of cryptococcal meningitis against that of existing diagnos

55 For cryptococcal meningitis, all-cause 2-week mortality was

56 201) of participants had confirmed CSF CrAg+ cryptococcal meningitis and 4% (54/1201) had neurologic

57 creased relative rate of 0.49 (P = 0.06) for cryptococcal meningitis and a decreased relative rate of

58 val of HIV-infected persons with symptomatic cryptococcal meningitis and asymptomatic, subclinical cr

59 e in the treatment of fungal infections like cryptococcal meningitis and C. albicans infections.

60 mouse IgG1 currently in clinical trials for cryptococcal meningitis and for the design of antibody t

61 ed adults in Uganda and South Africa who had cryptococcal meningitis and had not previously received

62 uman immunodeficiency virus (HIV)-associated cryptococcal meningitis and has been incorporated into W

63 body screening in four current patients with cryptococcal meningitis and identified and tested 103 ar

64 nvasive aspergillosis, invasive candidiasis, cryptococcal meningitis and mucosal and urinary Candida

65 We prospectively enrolled Ugandans with cryptococcal meningitis and obtained patient characteris

66 Two deaths occurred - one caused by cryptococcal meningitis and one by severe dementia with

67 The annual incidence of cryptococcal meningitis and Pneumocystis jirovecii pneum

68 to identify and treat those with subclinical cryptococcal meningitis and preemptive fluconazole for t

69 Postmortem cryptococcal meningitis and pulmonary cryptococcosis wer

70 uman studies have shown associations between cryptococcal meningitis and reduced IgM memory B cell le

71 Two others developed cryptococcal meningitis and survived.

72 Cryptococcal meningitis and tuberculosis are both import

73 Cryptococcal meningitis and tuberculosis are both import

74 mma 1b holds promise for patients with acute cryptococcal meningitis and warrants further study.

75 WHO-recommended treatment for HIV-associated cryptococcal meningitis and was associated with fewer ad

76 mortality among patients with HIV-associated cryptococcal meningitis and was associated with more adv

77 meningitis and sepsis), fungal (for example, cryptococcal meningitis) and parasitic (for example, mal

78 d to have symptoms, signs, or a diagnosis of cryptococcal meningitis) and those in treatment failure

79 ncidences of secondary P. carinii pneumonia, cryptococcal meningitis, and herpes zoster have declined

80 ART initiation (<=14 days) on outcomes from cryptococcal meningitis, and how to optimally manage ART

81 colony-stimulating factor autoantibodies and cryptococcal meningitis; anti-interleukin (IL)-6 autoant

82 with human immunodeficiency virus-associated cryptococcal meningitis are antiretroviral therapy (ART)

83 uman immunodeficiency virus (HIV)-associated cryptococcal meningitis are poorly defined.

84 Cryptococcal meningitis associated with human immunodefi

85 , none of the three reported adverse events (cryptococcal meningitis, asymptomatic anaemia, and asymp

86 We suggest that CrAg screening detects cryptococcal meningitis at an earlier stage, as evidence

87 rebrospinal fluid (CSF) of 209 patients with cryptococcal meningitis at baseline (day 0) and during a

88 measured in 44 patients with HIV-associated cryptococcal meningitis at baseline and during follow-up

89 al enrolled 48 adults with HIV and confirmed cryptococcal meningitis at two hospitals in Uganda.

90 mide group reported a serious adverse event (cryptococcal meningitis attributed to immune reconstitut

91 uman immunodeficiency virus (HIV)-associated cryptococcal meningitis, based on the results of the mul

92 lucytosine) is the recommended treatment for cryptococcal meningitis but has not been shown to reduce

93 gressive multifocal leucoencephalopathy, and cryptococcal meningitis) but also the AIDS dementia comp

94 is an important determinant of mortality in cryptococcal meningitis, but its use in aiding clinical

95 0,000 and culture positivity), and 27 had no cryptococcal meningitis by CrAg LFA or culture.

96 Cryptococcal meningitis can occur in persons with less-a

97 HIV-associated cryptococcal meningitis case fatality remains greater th

98 an Africa accounted for 73% of the estimated cryptococcal meningitis cases in 2014 (162 500 cases [95

99 In the United States, cryptococcal meningitis causes approximately 3400 hospit

100 lasma CRAG titers >1:640, 96% (27 of 28) had cryptococcal meningitis (cerebrospinal fluid CRAG-positi

101 individual-level CSF data from 3 sequential cryptococcal meningitis clinical trials conducted during

102 (25[OH]D) were measured in 150 patients with cryptococcal meningitis (CM) and 150 HIV-infected contro

103 ) or did not (HIV-infected controls) develop cryptococcal meningitis (CM) and HIV-uninfected persons

104 uman immunodeficiency virus (HIV)-associated cryptococcal meningitis (CM) and is lower in patients on

105 Ocular complications in cryptococcal meningitis (CM) are commonly attributed to

106 ated to raise intracranial pressure (ICP) in cryptococcal meningitis (CM) by mechanical obstruction o

107 Cryptococcal meningitis (CM) causes an estimated 180,000

108 Cryptococcal meningitis (CM) causes high rates of HIV-re

109 Cryptococcal meningitis (CM) causes substantial mortalit

110 y virus (HIV)-infected patients with treated cryptococcal meningitis (CM) commencing combination anti

111 human immunodeficiency virus/AIDS-associated cryptococcal meningitis (CM) frequently experience clini

112 iposomal amphotericin B (L-AmB) regimens for cryptococcal meningitis (CM) in Tanzania and Botswana.

113 Cryptococcal meningitis (CM) is a leading cause of death

114 Cryptococcal meningitis (CM) is a leading cause of funga

115 Cryptococcal meningitis (CM) is a leading cause of HIV-a

116 Cryptococcal meningitis (CM) is a major cause of death a

117 Cryptococcal meningitis (CM) is a major cause of morbidi

118 uman immunodeficiency virus (HIV)-associated cryptococcal meningitis (CM) is characterized by high fu

119 Cryptococcal meningitis (CM) is one of the most common c

120 Cryptococcal meningitis (CM) is the leading fungal cause

121 e in blood prior to the onset of symptomatic cryptococcal meningitis (CM), a leading cause of death a

122 study to determine the national incidence of cryptococcal meningitis (CM), and describe characteristi

123 forts to optimize therapy for HIV-associated cryptococcal meningitis (CM), survival outcomes remain p

124 Cryptococcal meningitis (CM)-related immune reconstituti

125 Cryptococcal meningitis (CM)-related mortality may be pr

126 among people with HIV (PWH) who present with cryptococcal meningitis (CM).

127 munodeficiency virus (HIV) who had suspected cryptococcal meningitis (CM).

128 mising as a strategy to reduce the burden of cryptococcal meningitis (CM).

129 patient, who defaulted from care, died from cryptococcal meningitis (CM).

130 ese case-control cohort (30 with symptomatic cryptococcal meningitis [CM], 30 without), both followed

131 uring human immunodeficiency virus (HIV) and cryptococcal meningitis coinfection are ill defined.

132 ive sertraline in adults with HIV-associated cryptococcal meningitis compared with placebo.

133 e cerebrospinal fluid (CSF) of patients with cryptococcal meningitis contains high levels of the chem

134 a in severely immunocompromised persons with cryptococcal meningitis contributes directly to this mor

135 a in severely immunocompromised persons with cryptococcal meningitis contributes directly to this mor

136 is unknown whether persons with symptomatic cryptococcal meningitis detected during routine blood cr

137 with 10 liver transplant recipients in whom cryptococcal meningitis developed after liver transplant

138 iagnosis prompted screening of patients with cryptococcal meningitis for anticytokine autoantibodies.

139 -up of previously healthy patients surviving cryptococcal meningitis found that cryptococcal antigen

140 ly enrolled Ugandans living with HIV who had cryptococcal meningitis from 2010-2012.

141 ectively enrolled HIV-infected Ugandans with cryptococcal meningitis from 2010-2012.

142 trial enrolled patients with HIV-associated cryptococcal meningitis from eight hospitals in Botswana

143 trial, we recruited HIV-positive adults with cryptococcal meningitis from two hospitals in Uganda.

144 0 (95% CI 150 600-282 400) incident cases of cryptococcal meningitis globally in 2014.

145 diagnostic testing and implementation of WHO cryptococcal meningitis guidelines.

146 One patient with cryptococcal meningitis had autoantibodies only against

147 Half of persons with advanced AIDS and cryptococcal meningitis had detectable CMV viremia.

148 No persons with cryptococcal meningitis had negative fingersticks.

149 cquired immunodeficiency syndrome (AIDS) and cryptococcal meningitis has been associated with high mo

150 Cryptococcal meningitis has been described in immunocomp

151 Cryptococcal meningitis has high mortality.

152 ubacute sclerosing panencephalitis (SSPE) or cryptococcal meningitis have been shown to represent Ab

153 ubacute sclerosing panencephalitis (SSPE) or cryptococcal meningitis have been shown to represent Ab

154 Toxoplasmosis, cryptococcal meningitis, herpes zoster, the wasting synd

155 ereas the global incidence of HIV-associated cryptococcal meningitis (HIV-CM) has decreased over the

156 l antigenemia are at high risk of developing cryptococcal meningitis if untreated.

157 for human immunodeficiency virus-associated cryptococcal meningitis in 4 sequential cohorts.

158 ntries, we assigned HIV-positive adults with cryptococcal meningitis in a 1:1 ratio to receive either

159 ier Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa trial were analyzed to

160 rapy have been proposed for the treatment of cryptococcal meningitis in AIDS patients.

161 ications for the treatment of HIV-associated cryptococcal meningitis in high-income settings.

162 the past ten years, standard diagnostics for cryptococcal meningitis in HIV-infected persons have evo

163 reduces the incidence of clinically evident cryptococcal meningitis in individuals living with advan

164 red therapy for the treatment of HIV-related cryptococcal meningitis in LMICs is 1 week of amphoteric

165 e high mortality associated with HIV-related cryptococcal meningitis in low-income and middle-income

166 r a trial on the treatment of HIV-associated cryptococcal meningitis in Mbarara, Uganda.

167 ureobasidin A, shows better efficacy against cryptococcal meningitis in mice than do clinically recom

168 ated tolerance limits treatment efficacy for cryptococcal meningitis in mice via inhibiting the synth

169 2-year-old woman who received a diagnosis of cryptococcal meningitis in November 1998.

170 antibodies are associated with some cases of cryptococcal meningitis in otherwise immunocompetent pat

171 Fluconazole is effective in the therapy of cryptococcal meningitis in patients with AIDS.

172 p, open-label trial of induction therapy for cryptococcal meningitis in patients with human immunodef

173 l to transform the management of HIV-related cryptococcal meningitis in resource-limited settings is

174 Patients with cryptococcal meningitis in sub-Saharan Africa frequently

175 of Cryptococcus infections in patients with cryptococcal meningitis in sub-Saharan Africa.

176 ause mortality in people with HIV-associated cryptococcal meningitis in sub-Saharan African countries

177 During lethal cryptococcal meningitis in the brain, C. neoformans sens

178 recruited adult patients with HIV-associated cryptococcal meningitis in Vietnam, Thailand, Indonesia,

179 Early ART initiation in cryptococcal meningitis increased CSF cellular infiltrat

180 We enrolled Ugandan adults with cryptococcal meningitis into an observational cohort rec

181 Cryptococcal meningitis is a common cause of AIDS-relate

182 Cryptococcal meningitis is a fungal infection in patient

183 Cryptococcal meningitis is a fungal infection, caused by

184 Cryptococcal meningitis is a leading cause of AIDS-relat

185 HIV-associated cryptococcal meningitis is a leading cause of AIDS-relat

186 Cryptococcal meningitis is a leading cause of human immu

187 Cryptococcal meningitis is a leading cause of meningitis

188 Cryptococcal meningitis is a life-threatening disease am

189 Cryptococcal meningitis is a major driver of global HIV-

190 Cryptococcal meningitis is a metric of HIV treatment pro

191 Identifying new antifungals for cryptococcal meningitis is a priority given the inadequa

192 We conclude that cryptococcal meningitis is a rare complication in liver

193 onotherapy, mortality because of HIV-related cryptococcal meningitis is approximately 70% in many Afr

194 HIV-associated cryptococcal meningitis is associated with an estimated

195 Cryptococcal meningitis is one of the most common life-t

196 Cryptococcal meningitis is the leading cause of adult me

197 Cryptococcal meningitis is the most common cause of adul

198 Cryptococcal meningitis is the most frequent cause of me

199 HIV-associated cryptococcal meningitis is the second leading cause of A

200 on and timing from asymptomatic infection to cryptococcal meningitis is unclear.

201 With cryptococcal meningitis, lower frequencies of expression

202 2-week cryptococcal meningitis mortality outcomes were similar

203 Cryptococcal meningitis occurs in 6 to 8% of human immun

204 y cryptococcosis are based on those used for cryptococcal meningitis or pneumonia.

205 but negative by the IMMY LFA, none developed cryptococcal meningitis over 3 months of follow-up witho

206 e four main types of CNS infection differed (cryptococcal meningitis p=0.0014, bacterial meningitis p

207 determining disease outcome in HIV-infected cryptococcal meningitis patients infected with Cryptococ

208 In cryptococcal meningitis phase 2 clinical trials, early f

209 ciency virus (HIV)-infected individuals with cryptococcal meningitis places them at risk for Cryptoco

210 h human immunodeficiency virus (HIV)-related cryptococcal meningitis receiving adjunctive flucytosine

211 s involving participants with HIV-associated cryptococcal meningitis receiving either daily liposomal

212 Antifungal treatment for cryptococcal meningitis relies on three old, off-patent

213 Cryptococcal meningitis remains a significant cause of d

214 n ART should be initiated after diagnosis of cryptococcal meningitis remains unanswered.

215 of the immune response in acute mortality of cryptococcal meningitis remains unclear.

216 Mortality from cryptococcal meningitis remains very high in Africa.

217 r antiretroviral therapy (ART) initiation in cryptococcal meningitis resulted in higher mortality com

218 The AMBITION-cm regimen for cryptococcal meningitis resulted in similar outcomes as

219 Altered mental status in cryptococcal meningitis results in poorer survival, but

220 uman immunodeficiency virus (HIV)-associated cryptococcal meningitis, screened for the Cryptococcal O

221 Only the incidences of cryptococcal meningitis, secondary P. carinii pneumonia,

222 lence tests with rabbit and murine models of cryptococcal meningitis showed that the serotype A conge

223 ccus gattii isolated from serial episodes of cryptococcal meningitis that were separated by at least

224 ated the role of microglia in the context of cryptococcal meningitis, the most common cause of fungal

225 For the initial treatment of AIDS-associated cryptococcal meningitis, the use of higher-dose amphoter

226 In this model of cryptococcal meningitis, there was evidence of a dose re

227 s the most attractive treatment strategy for cryptococcal meningitis, though the rising price may be

228 bacterial pneumonia, two tuberculosis, five cryptococcal meningitis, three had other infections, and

229 We measured CSF lactate in individuals with cryptococcal meningitis to determine its clinical signif

230 tomegalovirus co-infections in patients with cryptococcal meningitis to guide potential therapeutic i

231 ents with a first episode of AIDS-associated cryptococcal meningitis to treatment with higher-dose am

232 In an animal model of cryptococcal meningitis, topoisomerase I regulation was

233 and 189 ART-naive Ugandans with symptomatic cryptococcal meningitis treated with amphotericin (CM co

234 In the Advancing Cryptococcal Meningitis Treatment for Africa (ACTA) tria

235 Malawi, 236 participants from the Advancing Cryptococcal Meningitis Treatment for Africa trial were

236 addition of 5FC to FLU is cost-effective for cryptococcal meningitis treatment in Africa and, if made

237 model of care, we measured the prevalence of cryptococcal meningitis, tuberculous meningitis, bacteri

238 One survivor had suffered cryptococcal meningitis two years prior.

239 ng in predicting response in AIDS-associated cryptococcal meningitis using clinical isolates from a r

240 rring ART for 5 weeks after the diagnosis of cryptococcal meningitis was associated with significantl

241 d (CSF) from 337 Ugandans with first-episode cryptococcal meningitis was collected.

242 Survival from cryptococcal meningitis was higher in persons with prior

243 Mortality from cryptococcal meningitis was higher in recent ART initiat

244 Globally, cryptococcal meningitis was responsible for 15% of AIDS-

245 One patient with cryptococcal meningitis was successfully treated.

246 Patients with a first episode of cryptococcal meningitis were enrolled, and their immune

247 duals assessed, 172 HIV-infected adults with cryptococcal meningitis were enrolled.

248 Annual global deaths from cryptococcal meningitis were estimated at 181 100 (95% C

249 In this study, rabbits with experimental cryptococcal meningitis were given fluconazole at low, i

250 ntiretroviral naive patients presenting with cryptococcal meningitis were randomized to 4 treatment a

251 older with a first episode of HIV-associated cryptococcal meningitis were recruited to both trials.

252 t this hypothesis, we used a murine model of cryptococcal meningitis whereby cryptococci are introduc

253 in B with flucytosine induction regimens for cryptococcal meningitis, which are recommended in high-i

254 tibodies in an otherwise healthy female with cryptococcal meningitis who later developed pulmonary al

255 , we recruited HIV-infected individuals with cryptococcal meningitis who presented to Mulago Hospital

256 mmunodeficiency virus-infected patients with cryptococcal meningitis who received antifungal therapy

257 iciency virus-infected patients with treated cryptococcal meningitis who start combination antiretrov

258 identified seven HIV-negative patients with cryptococcal meningitis who tested positive for high-tit

259 tive participants, 138 (93%) had evidence of cryptococcal meningitis with a positive CSF CRAG.

260 icin B LNC formulation appears promising for cryptococcal meningitis with antifungal activity, simila

261 HIV-infected individuals developing cryptococcal meningitis with CD4 >=100 cells/muL present

262 idemiology, and updates on the management of cryptococcal meningitis with emphasis on HIV-associated

263 We review the antifungal drugs used to treat cryptococcal meningitis with respect to clinical effecti

264 rked interest in treating non-HIV-associated cryptococcal meningitis with single 10-mg/kg liposomal a

265 (1) examine whether patients diagnosed with cryptococcal meningitis within 14 days of ART initiation

266 Nine CSF samples from patients with cryptococcal meningitis yielded positive results using b